Quality of Life and Psychosocial Dimension in Children With Hypopituitarism

NCT ID: NCT05403255

Last Updated: 2022-06-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-01

Study Completion Date

2024-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Relatively little is known about the quality of life (QOL) of patients with hypopituitarism, particularly children. Quality of life studies have mostly focused on improvements following the initiation of growth hormone treatment in adults with growth hormone deficiency. Overall QOL data on patients with multiple pituitary hormone deficiency or another isolated deficiency are much scarcer. These studies suggest however that pituitary deficiencies affect the QOL and social integration of adults. In children, the psychosocial repercussions of the disease are very poorly understood, particularly in the case of multiple congenital pituitary hormone deficiency.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives:

* Describe the quality of life and psychosocial repercussions of the disease in children 10-17 years of age with multiple pituitary hormone deficiency (either acquired or congenital), or isolated pituitary hormone deficiency (other than idiopathic isolated growth hormone deficiency).
* Compare the QOL and psychosocial indicators of these patients with those of the general population
* Study the effects of various factors (medical, social, psychological) on patient outcomes and experiences of the disease.

Methods

* Prospective analytical pilot study involving the four hospitals in the Referral Centre for Rare Pituitary Diseases (Centre de Référence des Maladies Rares de l'Hypophyse, HYPO)
* Questionnaire data will be collected among patients and their parents during follow-up consultations.
* Children's quality of life will be evaluated using the Kidscreen-10 questionnaire (for children and parents) and PedsQL multidimensional fatigue scale. Psychosocial indicators (standard of living, schooling, recreation activities, social and family relationships, perceived health status and physical appearance) will be gathered using a questionnaire based on the HBSC (Health Behaviour in School-Aged Children) questionnaire (INPES 2010), and compared with data from the general population of elementary-, middle-and high-school children in France.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital or Acquired Hypopituitarism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multiple or isolated pituitary hormone deficiency group

Patient with multiple pituitary deficiency or isolated pituitary deficiency diagnosed for at least 6 months.

evaluation of the quality of life with questionnaires

Intervention Type OTHER

Questionnaire data will be collected among patients and their parents during follow-up consultations.

Children's quality of life will be evaluated using the Kidscreen-10 questionnaire (for children and parents) and PedsQL multidimensional fatigue scale. Psychosocial indicators (standard of living, schooling, recreation activities, social and family relationships, perceived health status and physical appearance) will be gathered using a questionnaire based on the HBSC (Health Behaviour in School-Aged Children) questionnaire (INPES 2010), and compared with data from the general population of elementary-, middle-and high-school children in France.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

evaluation of the quality of life with questionnaires

Questionnaire data will be collected among patients and their parents during follow-up consultations.

Children's quality of life will be evaluated using the Kidscreen-10 questionnaire (for children and parents) and PedsQL multidimensional fatigue scale. Psychosocial indicators (standard of living, schooling, recreation activities, social and family relationships, perceived health status and physical appearance) will be gathered using a questionnaire based on the HBSC (Health Behaviour in School-Aged Children) questionnaire (INPES 2010), and compared with data from the general population of elementary-, middle-and high-school children in France.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 10-17 years
* Multiple or isolated pituitary hormone deficiency
* Deficiency diagnosed for a least 6 months

Exclusion Criteria

* Isolated growth hormone deficiency with normal MRI findings and/or no previous irradiation of the hypothalamo-pituitary region and/or no known genetic cause.
* Secondary pituitary deficiency due to a secreting adenoma
* Inability to complete the questionnaire (intellectual disability, low French language proficiency)
* No health coverage
Minimum Eligible Age

10 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

François CREMIEUX

Role: STUDY_DIRECTOR

ASSISTANCE PUBLIQUE HOPITAUX MARSEILLE

Sarah CASTETS, PH

Role: PRINCIPAL_INVESTIGATOR

ASSISTANCE PUBLIQUE HOPITAUX MARSEILLE

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assistance Publique Hopitaux Marseille

Marseille, Bouches-du-Rhône, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sarah CASTETS, PH

Role: CONTACT

04 91 38 67 30

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Amandine ROLLAND

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A00504-39

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.